Assistive Technology for Cognition and Health-related Quality of Life in Huntington's Disease.
Assistive technology for cognition (ATC) can be defined as external devices aimed at supporting cognitive function. Studies in neurological populations suggest that use of ATC is a promising strategy to ameliorate negative effects of cognitive impairment and improve Health-related Quality of Life (HRQoL). There is a lack of studies on the effects of ATC in HD.



This study aimed to describe the use of ATC in patients with HD, and to investigate the association between ATC and HRQoL.



A cross-sectional population-based study, including eighty-four patients with a clinical HD diagnosis (stages I-V). Socio-demographic and clinical data were collected, including information regarding various aspects of ATC use and an evaluation of cognitive impairment was performed. The Unified Huntington's Disease Rating Scale (UHDRS) Total Functional Capacity scale (TFC) and the EQ-5D Visual Analogue Scale were used to evaluate functional ability and HRQoL. Descriptive analyses were conducted to describe ATC use and regression analyses to investigate associations between ATC and HRQoL.



Thirty-seven percent of the patients had ATC, and ATC was used most frequently in stages I-III. Information about ATC, needs evaluation and training was provided to 44%, 32.1% and 20.2% respectively. The regression analysis showed a significant association between TFC and HRQoL (β value = -0.564, p = 0.001), but there was no association between ATC and HRQoL.



One-third of all patients used ATC, mainly those with mild to moderate cognitive impairment (stage I -III). No association between ATC and HRQoL was found. More research is needed to investigate effects of ATC in HD.
Centre for Habilitation and Rehabilitation Models and Services (CHARM), Institute of Health and Society, University of Oslo, Blindern, Oslo, Norway.|Department of Neurohabilitation, Oslo University Hospital, Nydalen, Oslo, Norway.
Marleen R
MR
van Walsem
Centre for Habilitation and Rehabilitation Models and Services (CHARM), Institute of Health and Society, University of Oslo, Blindern, Oslo, Norway.|Department of Physical Medicine and Rehabilitation, Oslo University Hospital, Nydalen, Oslo, Norway.
Emilie I
EI
Howe
Institute of Health and Society, University of Oslo, Blindern, Oslo, Norway.|Department of Neurology, Oslo University Hospital, Nydalen, Oslo, Norway.
Jan C
JC
Frich
Centre for Habilitation and Rehabilitation Models and Services (CHARM), Institute of Health and Society, University of Oslo, Blindern, Oslo, Norway.|Department of Physical Medicine and Rehabilitation, Oslo University Hospital, Nydalen, Oslo, Norway.
Nada
N
Andelic
D000328:Adult; D000368:Aged; D003072:Cognition Disorders / Q000209:etiology* / Q000534:rehabilitation*; D018672:Community Health Planning; D003430:Cross-Sectional Studies; D005260:Female; D006306:Health Surveys; D006801:Humans; D006816:Huntington Disease / Q000150:complications / Q000453:epidemiology / Q000523:psychology; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D011788:Quality of Life / Q000523:psychology*; D012656:Self-Help Devices; D012720:Severity of Illness Index; D018709:Statistics, Nonparametric; D064232:Visual Analog Scale
Neurodegenerative diseases; cognition; huntington disease; quality of life; self-help devices
Mov Disord. 2009 Mar 15;24(4):574-8
19097181
J Huntingtons Dis. 2013;2(2):159-75
25063513
Eur J Public Health. 2013 Feb;23(1):45-9
22434205
Lancet Neurol. 2013 Jul;12(7):637-49
23664844
NeuroRehabilitation. 2015;37(3):315-9
26518529
J Neural Transm (Vienna). 2012 Nov;119(11):1361-5
22398875
Brain Res Bull. 2009 Oct 28;80(4-5):192-5
19576265
Neurodegener Dis Manag. 2015;5(2):155-64
25894879
J Neurol Neurosurg Psychiatry. 2001 Apr;70(4):477-82
11254770
Disabil Rehabil. 2005 Jul 8;27(13):731-9
16096225
J Int Neuropsychol Soc. 2012 Jan;18(1):1-19
22152338
Tremor Other Hyperkinet Mov (N Y). 2014 Apr 14;4:223
24761312
NeuroRehabilitation. 1994;4(3):174-86
24525366
Int J Lang Commun Disord. 2010 Sep-Oct;45(5):523-36
20874057
NeuroRx. 2004 Apr;1(2):263-72
15717027
Neurosci Biobehav Rev. 2013 Mar;37(3):480-90
23376047
Health Policy. 1991 Jun;18(1):25-36
10112299
Front Biosci (Schol Ed). 2013 Jan 01;5:1-18
23277034
Health Policy. 1990 Dec;16(3):199-208
10109801
J Neurosci Methods. 2016 May 30;265:19-24
26719240
Mov Disord. 2014 Apr 15;29(5):673-83
24757115
Clin Rehabil. 2010 Aug;24(8):701-14
20543021
Aging Ment Health. 2003 Jan;7(1):22-7
12554311
BMC Geriatr. 2008 Nov 07;8:28
18992135
Qual Life Res. 2015 Aug;24(8):1963-71
25636661
Curr Neurol Neurosci Rep. 2011 Oct;11(5):474-83
21861097
Brain Res Bull. 2007 Apr 30;72(2-3):175-8
17352943
Disabil Rehabil Assist Technol. 2010;5(5):339-50
20568962
Mov Disord. 2014 Sep 15;29(11):1351-8
25216368
J Nerv Ment Dis. 2004 Jan;192(1):72-4
14718780
Orphanet J Rare Dis. 2011 Nov 18;6:77
22094174
Clin Genet. 2012 Feb;81(2):117-22
22151007
Neuropsychology. 2011 Jan;25(1):1-14
20919768
NeuroRehabilitation. 2015;37(3):379-92
26484523
Neuropsychol Rehabil. 2014;24(3-4):419-44
23957379
Disabil Rehabil Assist Technol. 2016 Aug;11(6):493-500
25434402
Disabil Rehabil Assist Technol. 2013 Jan;8(1):67-76
22204703
J Nurs Scholarsh. 2005;37(4):336-42
16396406
Nervenarzt. 2015 Feb;86(2):167-73
25659843
NeuroRehabilitation. 2015;37(3):359-78
26518531
J Neurol Neurosurg Psychiatry. 2008 Aug;79(8):874-80
18096682